ArticlePLoS genetics2020
In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.
Open access · goldAbstract read
In one paragraph
Article in PLoS genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 32 citations in OpenAlex.
- Progesterone induces steroidome and lipidome remodeling in a BRCA-resembling mouse model of high-grade serous ovarian cancer.Translational oncology · 2026Article
- The uterine secretome initiates growth of gynecologic tissues in ectopic locations: re-evaluating the evidence.Pathology oncology research : POR · 2026Review
- Models of high-grade serous carcinoma of tubo-ovarian origin.Oncology reviews · 2026Review
- Loss ofOncotarget · 2025Article
- Reciprocal crosstalk between Th17 and mesothelial cells promotes metastasis-associated adhesion of ovarian cancer cells.Clinical and translational medicine · 2024Article
- Review
- TRAIL-dependent apoptosis of peritoneal mesothelial cells by NK cells promotes ovarian cancer invasion.iScience · 2023Article
- Ultrahigh Resolution Lipid Mass Spectrometry Imaging of High-Grade Serous Ovarian Cancer Mouse Models.bioRxiv : the preprint server for biology · 2023Article
- Untargeted metabolomics analysis on kidney tissues from mice reveals potential hypoxia biomarkers.Scientific reports · 2023Article
- Machine Learning Reveals Lipidome Remodeling Dynamics in a Mouse Model of Ovarian Cancer.Journal of proteome research · 2023Article
- Machine Learning Reveals Lipidome Remodeling Dynamics in a Mouse Model of Ovarian Cancer.bioRxiv : the preprint server for biology · 2023Article
- In Vitro Models of Ovarian Cancer: Bridging the Gap between Pathophysiology and Mechanistic Models.Biomolecules · 2023Review
- Ultrahigh resolution lipid mass spectrometry imaging of high-grade serous ovarian cancer mouse models.Frontiers in chemistry · 2023Article
- Hippo Signaling in the Ovary: Emerging Roles in Development, Fertility, and Disease.Endocrine reviews · 2022Review
- Space- and Time-Resolved Metabolomics of a High-Grade Serous Ovarian Cancer Mouse Model.Cancers · 2022Article
- Silencing of SBF2-AS1 inhibits cell growth and invasion by sponging microRNA-338-3p in serous ovarian carcinoma.The Kaohsiung journal of medical sciences · 2022Article
- USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model.Oncogene · 2022Article
- Intra-Tumoral Nerve-Tracing in a Novel Syngeneic Model of High-Grade Serous Ovarian Carcinoma.Cells · 2021Article
- A Benzenesulfonamide-Based Mitochondrial Uncoupler Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Epithelial Ovarian Cancer.Molecular cancer therapeutics · 2021Article
- Neutrophil Extracellular Traps: A New Player in Cancer Metastasis and Therapeutic Target.Journal of experimental & clinical cancer research : CR · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 16 institutions in 3 countries.
Olga KimDepartment of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Eun Young ParkDepartment of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.ORCID 0000-0001-8159-539X
David L KlinkebielDepartment of Biochemistry and Molecular Biology, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.ORCID 0000-0001-9963-8909
Svetlana D PackLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID 0000-0003-3256-6626
Yong-Hyun ShinDepartment of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Zied AbdullaevLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID 0000-0001-6345-2088
Robert E EmersonDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Donna M CoffeyDepartment of Pathology and Genomic Medicine, Houston Methodist and Weill Cornell Medical College, Houston, Texas, United States of America.ORCID 0000-0002-1030-8565
Sun Young KwonDepartment of Pathology, School of Medicine, Keimyung University, Daegu, Republic of Korea.ORCID 0000-0002-8410-0185
Chad J CreightonDepartment of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.ORCID 0000-0002-6090-703X
Sanghoon KwonResearch and Development Center, Bioway Inc, Seoul, Republic of Korea.ORCID 0000-0002-3089-0636
Edmund C ChangHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, United States of America.ORCID 0000-0003-1815-5548
Theodore ChiangHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, United States of America.
Alexander N YatsenkoDepartment of Obstetrics, Gynecology & Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Jeremy ChienDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California, United States of America.ORCID 0000-0003-4744-8374
Dong-Joo CheonDepartment of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, NY, United States of America.ORCID 0000-0002-6134-4902
Yang Yang-HartwichDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, United States of America.
Harikrishna NakshatriDepartment of Surgery, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.ORCID 0000-0001-8876-0052
Kenneth P NephewMedical Sciences Program, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Bloomington, Indiana, United States of America.
Richard R BehringerDepartments of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Facundo M FernándezSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Chi-Heum ChoDepartment of Obstetrics and Gynecology, School of Medicine, Keimyung University, Daegu, Republic of Korea.ORCID 0000-0002-0437-4099
Barbara VanderhydenDepartment of Cellular and Molecular Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.ORCID 0000-0002-7644-7189
Ronny DrapkinPenn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-6912-6977
Robert C BastDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Kathy D MillerDepartment of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine Indianapolis, Indiana, United States of America.
Adam R KarpfEppley Institute for Cancer Research, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.ORCID 0000-0002-0866-0666
Jaeyeon KimDepartment of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.ORCID 0000-0003-2811-8281
Indiana University Health · USBaylor College of Medicine · USKeimyung University · KRNational Institutes of Health · USThe University of Texas MD Anderson Cancer Center · USUniversity of Nebraska Medical Center · USAlbany Medical Center Hospital · USCancer Research Center · USGeorgia Institute of Technology · USHouston Methodist · USIndiana University Bloomington · USIndiana University School of MedicineUniversity of California, Davis · USUniversity of Ottawa · CAUniversity of Pittsburgh · USYale University · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MProject IIIP50HD096723 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Kyle Edwin Orwig · 2019 to 2026
$15.0MU.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C, SOOD, ANIL K · 2017 to 2021
$7.9MDeep Ovarian Cancer MetabolomicsR01CA218664 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI Facundo Martin Fernandez, Jaeyeon Kim · 2018 to 2026
$4.3MUnderstanding the origin,initiation,and progression of high-grade serous ovarian cancerR00CA179137 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI KIM, JAEYEON · 2016 to 2018
$731kMolecular Mechanisms of Cancer DevelopmentZICBC011842 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PACK, SVETLANA · 2018 to 2020
$458kNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA217685NCI NIH HHS R00 CA179137NCI NIH HHS R01 CA218664NICHD NIH HHS P50 HD096723
Abstract
Metastasis is responsible for 90% of human cancer mortality, yet it remains a challenge to model human cancer metastasis in vivo. Here we describe mouse models of high-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), the most common and deadliest human ovarian cancer type. Mice genetically engineered to harbor Dicer1 and Pten inactivation and mutant p53 robustly replicate the peritoneal metastases of human HGSC with complete penetrance. Arising from the fallopian tube, tumors spread to the ovary and metastasize throughout the pelvic and peritoneal cavities, invariably inducing hemorrhagic ascites. Widespread and abundant peritoneal metastases ultimately cause mouse deaths (100%). Besides the phenotypic and histopathological similarities, mouse HGSCs also display marked chromosomal instability, impaired DNA repair, and chemosensitivity. Faithfully recapitulating the clinical metastases as well as molecular and genomic features of human HGSC, this murine model will be valuable for elucidating the mechanisms underlying the development and progression of metastatic ovarian cancer and also for evaluating potential therapies.
Indexed as
AnimalsAntineoplastic AgentsCell Line, TumorChromosomal InstabilityCystadenocarcinoma, SerousDEAD-box RNA HelicasesDisease Models, AnimalDNA RepairDrug Resistance, NeoplasmDrug Screening Assays, AntitumorFeasibility StudiesFemaleHumansMiceMice, KnockoutMutationAntineoplastic AgentsDEAD-box RNA HelicasesDicer1 protein, mousePTEN PhosphohydrolasePten protein, mouseRibonuclease IIITrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.